Jnana goes after metabolism-mediating proteins, gains Roche as partner

Jnana screens for small molecules that bind to solute carriers

Jnana is developing small molecules against a relatively untapped class of proteins -- solute carriers -- to modulate cell metabolism. On Tuesday, the biotech closed its first deal with a large biopharma, partnering with Roche for $40 million up front to apply its RAPID platform to immune-mediated and neurological diseases.

The company launched in 2017 with a $50 million series A round. Its co-founders include serial entrepreneur Stuart Schreiber, a professor of chemistry and chemical biology at Harvard University and one

Read the full 800 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE